- This post hoc analysis looked at the more stringent viral load measures of <40 copies/mL and TND in a subpopulation of the SALSA study


SALSA Efficacy

ROBUST EFFICACY IN DIVERSE PATIENT POPULATIONS
Non-Inferiority Maintained With No Increased Risk of Virological Failure1
Adjusted Treatment Difference (95% CI)

Virological Outcomes at 48 Weeks

Adapted from Llibre et al, 2021.1
ITT–E Snapshot analysis.
ITT–E=intent-to-treat–exposed.
VIROLOGICAL OUTCOMES BY SUBGROUP ARE CONSISTENT WITH OVERALL EFFICACY RESULTS
Virological Outcomes by Subgroup at Week 48 (Snapshot Analysis; ITT–E)2

Adapted from Taylor et al, 2021.2
EFFICACY REINFORCED AT 48 WEEKS WITH MORE STRINGENT VIRAL LOAD MEASURES
Proportion of Patients With <40 copies/mL and TND at Last Available On-treatment Was High and Comparable Across Arms3

Adapted from Underwood et al, 2022.3
ADVERSE EVENTS LEADING TO WITHDRAWAL WERE SIMILAR ACROSS ARMS1

Adapted from Llibre et al, 2021.1
AE=adverse event; SAE=serious adverse event.
References:
- Llibre JM, Alves Brites C, Cheng C-Y, et al. Switching to the 2-drug regimen of dolutegravir/lamivudine (DTG/3TC) fixed-dose combination is noninferior to continuing a 3-drug regimen through 48 weeks in a randomized clinical trial (SALSA). Presented at: International AIDS Society Conference on HIV Science; July 18-21, 2021; Virtual. Slides OALB0303.
- Taylor S, Andrade-Villanueva J, Kaplan R, et al. Switching to DTG/3TC is non-inferior to continuing current antiretroviral regimen at week 48: SALSA subgroup analyses. Presented at: 18th European AIDS Conference; October 27-30, 2021; London, England. Poster PE2/72.
- Underwood M, Osiyemi O, Rubio R, et al. Archived resistance and response to <40 c/mL and TND—DTG/3TC FDC at week. 48 in SALSA. Presented at: Conference on Retroviruses and Opportunistic Infections; February 12-16, 2022; Virtual. Poster 481.
Dovato is a registered trade mark of the ViiV Healthcare group of companies or its licensor.
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
Date of Preparation: March 2024
PM-IE-DLL-WCNT-240004